



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Richard T. Dean et al.

Art Unit : 1654

Serial No.: 08/236,402

Examiner : Jeffrey Russel

Filed : May 2, 1994

Title : TECHNETIUM-99M LABELED IMAGING AGENTS

#50
M.G.J
8/28/03

DECLARATION UNDER 37 C.F.R. § 1.132

I, JOHN LISTER-JAMES, declare as follows:

1. I reside in Bedford, New Hampshire.
2. I received my B.Sc., with honors, in chemistry from Imperial College of the University of London in 1974, and I was awarded my Ph.D. in organic chemistry from the University of London in 1981. From 1981 to 1986 I was a Research Fellow in Radiology (Nuclear Medicine), Children's Hospital, Boston, Massachusetts. During the same time I was a Visiting Scientist at the Massachusetts Institute of Technology, Cambridge, Massachusetts. From 1983 to 1986 I was also an Associate in Radiology (Nuclear Medicine), Harvard Medical School, Boston, Massachusetts. During this period, my research included the design and synthesis of technetium complexes, the design, synthesis and evaluation of ^{99m}Tc-labelled radiopharmaceuticals, the investigation of structure/activity relationships probing biochemical processes and the development of new methods in organic synthesis. From 1987 to 1990 I was employed at Centocor, Inc., Malvern, Pennsylvania, in various senior positions. At Centocor, I supervised the product development support for, wrote sections of, and coordinated the completion of the technical sections of US and European Product License Applications for a radioimmuno diagnostic product. I also supervised technical projects supporting Product License Application submissions, and I supervised a group of senior and associate

scientists in the development of novel protein modification and radiolabelling methods leading to proprietary and potentially commercially valuable technology. From 1990 to 1999, I was employed by Diatide, Inc. (formerly Diatech, Inc.) in various management positions, including Director of R&D, Director of Regulatory Affairs, Director of Product Development, Senior Director of R&D, Vice President of Science & Technology. During this time I was responsible for various aspects of radiopharmaceutical R&D, in particular of radiopharmaceuticals based upon technetium labeled peptides. At different times during this period I was responsible for drug discovery, intellectual property, product development, preclinical pharmacology and toxicology and regulatory affairs. In 1999, Berlex Laboratories, Inc. acquired Diatide, Inc., and since 1999 I have been employed by Berlex. I am currently Vice President, Research & Development, Berlex Diagnostic Imaging and Radiopharmaceuticals. I am currently responsible for a research and development group involved in radiopharmaceutical drug discovery, chemistry, manufacturing and controls development, and clinical development of radiopharmaceuticals.

3. I am an inventor in the 58 patents set forth in the attached Exhibit 1 and an author of numerous scientific articles, including those listed in Exhibit 2 attached hereto.


4. I am also an inventor in 2 recently issued United States Patents shown in the attached Exhibit 2.

5. I have been asked to review and comment on certain references cited by the Examiner in rejecting various claims in this patent application. In particular, I am submitting this declaration in support of the concept that technetium will bind to an -S-N-N-S- chelator in preference to an -N-N-N-S- chelator.

6. Technetium is most readily available in the +7 oxidation state as pertechnetate. In order to cause it to bind to other molecules, the technetium must be reduced to a lower oxidation state. The first and most accessible reduced form of technetium is the +5 oxidation state, formed by a two-electron reduction of pertechnetate. The most common two-electron reducing agent used in technetium-99m-based radiopharmaceuticals is stannous ion in the form of a stannous salt such as stannous chloride, although other reductants can be used. In order to radiolabel a specific-binding molecule with the reduced technetium, the technetium must be bound as a coordination complex with a ligand that is part of, or covalently linked to, the specific-binding molecule.

7. In its +5 oxidation state, technetium normally forms square pyramidal complexes with one oxo ligand and 4 other donor ligands. In this form, technetium is thiophilic, preferring thiolate, *i.e.*, sulfur (+2), donor ligands. This was exemplified in an article by DePamphilis et al. – Bruno V. DePamphilis, Alun G. Jones and Alan Davison, "Ligand-Exchange Reactivity Patterns of Oxotechnetium(V) Complexes", Inorg. Chem. 22:2292-2297 (1983) – copy attached as Exhibit 3. The authors reported that, when reacted with 2-mercaptoacetic acid (a/k/a thioglycolic acid) having the molecular structure HSCH_2COOH , technetium in the +5 oxidation state preferentially formed a bis-(2-mercapto-thiolacetic acid) complex with the 2-mercapto-thiolacetic acid (molecular structure HSCH_2COSH) present as an impurity in the 2-mercapto-acetic acid.

8. In addition, it has been shown that stable oxo complexes of technetium (+5) can be formed from bisamide bisthiol ligands.



See, Alan Davison, Alun G. Jones, Chris Orvig and Miriam Sohn, "New Class of Oxotechnetium (5+) Chelate Complexes Containing a TcON_2S_2 Core", Inorg. Chem. 6:1629-1632 (1981) – copy attached as Exhibit 4. In Dean et al. U.S. Patent No. 5,561,220, and in Dean et al. U.S. Patent No. 6,017,510, the inventors have claimed compositions for radiolabelling specific binding peptides using such ligands presenting -Cys-amino acid-Cys- sequences (with the cysteine thiol groups initially in technetium-cleavable protected form).

9. Therefore, it is expected that, when presented with a molecule containing more than one thiol donor ligand, technetium will bind preferentially to both thiols when there are two available, or to as many as four thiols if present and configurationally possible.

10. Although it is now known that technetium (+5) can form stable oxo complexes with single thiol containing ligands, such as mercaptoacetyl-Gly-Gly-Gly, the known thiophilicity of technetium would cause one to expect that, when more than one thiol group is available for binding, technetium will form a complex across two or more thiol groups.


11. Therefore, in a peptide sequence such as peptide -Gly-Gly-Cys-Gly-Cys-Gly-Gly-peptide, it would be expected that technetium will form an oxo complex with the -Cys-Gly-Cys- sequence, in preference to forming a complex with either the -Gly-Gly-Cys- or -Cys-Gly-Gly- sequences. This is even more likely considering that, for bisamide bithiol complexes of technetium (+5), ligands that form 5 or 6 membered rings with the technetium are preferred (Exhibit 4). The sequence -Cys-Gly-Cys- is a ligand of this type.

Applicant : Richard T. DEAN et al.
Serial No. : 08/236,402
Filed : May 2, 1994
Page : 5 of 5

Attorney's Docket No.: 09744-006001 / DITI 107

I declare further that all statements made of my own knowledge are true and all statements made on information and belief are believed to be true. I make this declaration understanding that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful statements may jeopardize the validity of this application or any patent issuing thereon.

Signed at Londonderry, New Hampshire, this 30 day of June 2003.



John Lister-James

J. Lister-James Bibliography

Refereed Papers:

1. Alker D, Barton DHR, Hesse RH, Lister-James J, Markwell RE, Pechet MM, Rozen S, Takeshita T, Toh HT. Selective Fluorination at Tertiary Centres in Steroids and Adamantanoids using Fluorooxytrifluoromethane and using Molecular Fluorine. *N J Chem* 1980;4:239-254
2. Barton DHR, Lister-James J, Hesse RH, Pechet MM, Rozen S. Electrophilic Fluorination of some Steroidal, α,β -Unsaturated Ketones. *J Chem Soc, Perkin I* 1982;1105-1110
3. Barton DHR, Choi LSL, Lister-James J, Hesse RH, Pechet MM. Preparation and Reactions of some Steroidal Cross-Conjugated 3-Nitrones. *J Chem Soc, Perkin I* 1983;2599-2606
4. Brenner D, Davison A, Lister-James J, Jones AG. The Synthesis and Characterization of a Series of Isomeric Oxotechnetium(+5) Bisamido Bisthiolates. *Inorg Chem* 1984;23:3793-3797
5. Holman BL, Jones AG, Lister-James J, Davison A, Abrams MJ, Kirshenbaum JM, Tumeh SS, English RJ. A New Tc-99m-Labeled Myocardial Imaging Agent, Hexakis(t-Butylisonitrile)-Technetium(I) [Tc-99m TBI]: Initial Experience in the Human. *J Nucl Med* 1984;25:1350-1355
6. Holman BL, Lee RGL, Hill TC, Lovett RD, Lister-James J. A Comparison of Two Cerebral Perfusion Tracers, N-Isopropyl I-123 p-Iodoamphetamine and I-123 HIPDM, in the Human. *J Nucl Med* 1984;25:25-30
7. Polak JF, Holman BL, Moretti J-L, Eisner RL, Lister-James J, English RJ. I-123 HIPDM Brain Imaging with a Rotating Gamma Camera and a Slant-Hole Collimator. *J Nucl Med* 1984;25:495-498
8. Campbell S, Holman BL, Kirshenbaum JM, Antman EM, Lister-James J, Davison A, Koslowski J, English RJ, Jones AG. The Scintigraphic Evaluation of Myocardial Infarction and Regional Ventricular Performance using Technetium-99m Hexakis(t-Butylisonitrile) technetium(I)(TBI), A New Myocardial Imaging Agent. *Eur J Nucl Med* 1986;12:219-225
9. English RJ, Jones AG, Davison A, Lister-James J, Campbell S, Holman BL. Imaging Considerations for a Technetium-99m Myocardial Perfusion Agent. *J Nucl Med Tech* 1986;14:6
10. Holman BL, Campbell CI, Lister-James J, Jones AG, Davison A, Kloner RA. The Effect of Reperfusion and Hyperemia on the Biodistribution in Dogs of the Myocardial Imaging Agent ^{99m}Tc-TBI. *J Nucl Med* 1986;27:1172-1177
11. Sia STB, Holman BL, McKusick K, Rigo P, Gillis F, Sporn V, Perez-Balino N, Mitta A, Vosberg H, Szabo Z, Schwartzkopff B, Moretti J-L, Davison A, Lister-James J, Jones AG. The Utilization of Tc-99m TBI as a Myocardial Perfusion Agent in Exercise Studies; Comparison with Tl-201 Thallous Chloride and Examination of Its Biodistribution in Humans. *Eur J Nucl Med* 1986;12:333-336
12. Holman BL, Sporn V, Jones AG, Sia STB, Perez-Balino N, Davison A, Lister-James J, Kronauge JF, Mitta AEA, Camin LL, Campbell S, Williams SJ, Carpenter

- AT. Myocardial Imaging with Technetium-99m CPI-Initial Experience in the Human. *J Nucl Med* 1987;28:13-18
13. Sia ST, Holman BL, Campbell S, Lister-James J, English RJ, Kronauge JF, Davison A, Jones AG. The Utilization of Technetium-99m CPI as a Myocardial Perfusion Imaging Agent in Exercise Studies. *Clin Nucl Med* 1987;12:681-687
14. Bryson N, Dewan JC, Lister-James J, Jones AG, Davison A. Neutral Technetium(V) Complexes of Amide Thiol Thioether Chelating Ligands. *Inorg Chem* 1988;27:2154-2161
15. Piwnica-Worms D, Kronauge JF, Holman BL, Lister-James J, Davison A, Jones AG. Hexakis (carbomethoxyisopropylisonitrile) technetium(I), a New Myocardial Perfusion Imaging Agent: Binding Characteristics in Cultured Chick Heart Cells. *J Nucl Med* 1988;29:55-61
16. Bryson NJ, Brenner B, Lister-James J, Jones AG, Dewan JC, Davison A. Synthesis and Molecular Structure of a "Lantern" Dimer (AsPh_4)₂[$\text{Tc}_2\text{O}_2(\text{SCH}_2\text{CONHCH}_2\text{CH}_2\text{NHCOCH}_2\text{S})_4$]. *Inorg Chem* 1989;28:3825-3828
17. Weber RW, Boutin RH, Nedelman MA, Lister-James J, Dean RT. Enhanced Kidney Clearance with an Ester-Linked $^{99\text{m}}\text{Tc}$ -Radiolabeled Antibody Fab'-Chelator Conjugate. *Bioconjugate Chem* 1990;1:431-437
18. Bryson N, Lister-James J, Jones AG, Davis WM, Davison A. Protecting Groups in the Preparation of Thiolate Complexes of Technetium. *Inorg Chem* 1990;29:2948-2951
19. Weber RW, Boutin RH, Nedelman MA, Lister-James J, Dean RT. Enhanced Kidney Clearance with an Ester-Linked Technetium-99m Radiolabeled Antibody Fab'-Chelator Conjugate. *Bioconjugate Chem* 1991;1:431-437
20. Hardoff R, Braegelman F, Zanzonico P, Herrold EM, Lees RS, Lees AM, Dean RT, Lister-James J, Borer JS. External Imaging of Atherosclerosis in Rabbits using an ^{123}I -Labeled Synthetic Peptide Fragment. *J Clin Pharm* 1993;33:1039-1047
21. Muto P, Lastoria S, Varrella P, Vergara E, Salvatore M, Morgano G, Lister-James J, Bernardy JD, Dean RT, Wencker D, Borer JS. Detecting Deep Venous Thrombosis with Technetium-99m-Labeled Synthetic Peptide P280. *J Nucl Med* 1995;36:1384-1391
22. Hardoff R, Zanzonico P, Braegelman F, Herrold EM, Lees RS, Lees AM, Dean RT, Lister-James J, Borer JS. Localization of $^{99\text{m}}\text{Tc}$ -labeled Apob Synthetic Peptide in Arterial Lesions of an Experimental Model of Spontaneous Atherosclerosis. *Amer J Therap* 1995;2:88-99
23. Lister-James J, Moyer BR, Dean RT. Small Peptide Radiolabeled with $^{99\text{m}}\text{Tc}$. *QJ Nucl Med* 1996;40:221-233
24. Lister-James J, Knight LC, Maurer AH, Bush LR, Moyer BR, Dean RT. Thrombus Imaging with a Technetium-99m-Labeled, Activated Platelet Receptor-Binding Peptide. *J Nucl Med* 1996;37:775-781
25. Moyer BR, Vallabhajosula S, Lister-James J, Bush LR, Cyr JE, Snow DA, Bastidas A, Lipszyca H, Dean RT. Technetium-99m-White Blood Cell-Specific Imaging Agent Developed from Platelet Factor-4 to Detect Infection. *J Nucl Med* 1996;27:673-679
26. Pearson DA, Lister-James J, McBride WJ, Wilson DM, Martel LJ, Civitello ER, Dean DT. Thrombus Imaging using Technetium-99m-Labeled High-Potency

- GPIIb-IIIa Receptor Antagonists. Chemistry and Initial Biological Studies. J Medicinal Chem 1996;39:1372-1382
27. Pearson DA, Lister-James J, McBride WJ, Wilson DM, Martel LJ, Civitello ER, Taylor JE, Moyer BR, Dean RT. Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m: Chemistry and Initial Biological Studies. J Medicinal Chem 1996;39:1361-1371
 28. Vallabhajosula S, Moyer BR, Lister-James J, McBride BJ, Lipszyc H, Lee H, Bastidas D, Dean RT. Preclinical Evaluation of Technetium-99m-Labeled Somatostatin Receptor-Binding Peptides. J Nucl Med 1996;37:1016-1022
 29. Lu P, Zanzonico P, Lister-James J, Goldfine SM, Herrold E, Lees RS, Lees AM, Dean RT, Moyer BR, Borer JS. Biodistribution and Autoradiographic Localization of I-125 -Labeled Synthetic Peptide in Aortic Atherosclerosis in Cholesterol-Fed Rabbits. Amer J Ther 1996;3:673-680
 30. Lister-James J, Moyer BR, Dean RT. Pharmacokinetic Considerations in the Development of Peptide-Based Imaging Agents. QJ Nucl Med 1997;41:111-118
 31. Lister-James J, Vallabhajosula S, Moyer BR, Pearson DA, McBride BJ, De Rosch MA, Bush LR, Machac J, Dean RT. Pre-Clinical Evaluation of Technetium-99m Platelet Receptor-Binding Peptide. J Nucl Med 1997;38:105-111
 32. Lister-James J, Moyer BR, Dean RT. Pharmacokinetic Considerations in the Development of Peptide-Based Imaging Agents. QJ Nucl Med 1997; 41:111-118
 33. Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, Pangerl T, Gludovacz D, Peck-Radosavljevic M, Lister-James J, Hamilton G, Kaserer K, Valent P, Dean R. Somatostatin Receptor Subtype Specificity and *in Vivo* Binding of a Novel Tumor Tracer, ^{99m}Tc-P829. Cancer Res 1998;58:1850-1859
 34. Nicodemus CF, Moyer Br, Lister-James J. In Vivo Leukocytes Labeling Using a Platelet Factor 4-Derived Heparin Binding Peptide Technetium Complex. Int Arch Allergy Immunol 1999;118:362-363
 35. Lister-James J, Dean RT. Tc-99m P829: Characterization of a Technetium-99-Labeled Somatostatin Receptor-Binding Peptide. In: Nicolini M, Mazzi U, ed. Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine. Padua: SGE; 1999:473-478
 36. Lister-James J, Dean RT. Tc-99m P829: Tumor Imaging with a Technetium-99-Labeled Somatostatin-Receptor Binding Peptide. In: Nicolini M, Mazzi U, ed. Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine. Padua: SGE; 1999:769-774
 37. Lister-James J, Dean RT. Technetium-99m-Labeled Receptor-Specific Small Synthetic Peptides: Practical Imaging Agents of Biochemical Markers. In: Nicolini M, Mazzi U, ed. Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine. Padua: SGE; 1999:401-407
 38. Blum J, Handmaker H, Lister-James J, Rinne N. A Multicenter Trial with a Somatostatin Analog ^{99m}Tc Depreotide in the Evaluation of Solitary Pulmonary Nodules. Chest. 2000; 117:1232-1238
 39. Taillefer R, Edell S, Innes G, Lister-James J. Acute Thromboscintigraphy with ^{99m}Tc-Apcitide: Results of the Phase 3 Multicenter Clinical Trial comparing ^{99m}Tc-Apcitide Scintigraphy with Contrast Venography for Imaging Acute DVT. J Nucl Med. 2000;41:1214-1223

40. Palestro CJ, Weiland FL, Seabold JE, Valdivia S, Tomas MB, Moyer BR, Baran YM, Lister-James J, Dean RT. Localizing Infection with a Technetium-99m-Labeled Peptide: Initial Results. *Nuclear Medicine Communications*, 2001;22:695-701.

Book Chapters:

1. Lister-James J. Single-Photon Radiopharmaceuticals. In: Holman BL (ed). *Radionuclide Imaging of the Brain*. New York. Churchill Livingstone, 1985

Patents:

1. Davison A, Brenner D, Lister-James J, Jones AG. Bisamide Bisthiol Compounds Useful for Making Technetium Radiodiagnostic Renal Agents. (U.S. Patent 4,673,562; June 16, 1987)
2. Jones AG, Lister-James J, Davison A. Technetium Radiodiagnostic Fatty Acids Derived from Bisamide Bisthiol Ligands. (U.S. Patent 4,746,505; May 14, 1988)
3. Dean RT, Boutin RH, Lister-James J. Proteins Conjugates with Positively Charged Molecules with Decreased Blood Clearance Rates. (U.S. Patent 5,162,505; November 10, 1992)
4. Dean RT, Lister-James J, Boutin RH. Crosslinking Protein Compositions having two or more Identical Binding Sites for Targeting Therapy or Diagnosis. (U.S. Patent 5,185,433; February 9, 1993)
5. Dean RT, Lister-James J, Buttram S. Technetium-99m Labeled Somatostatin-Derived Peptides for Imaging. (U.S. Patent 5,225,180; July 6, 1993)
6. Dean RT, Lister-James J, Buttram S. Technetium-99m Labeled Somatostatin-Derived Peptides for Imaging. (U.S. Patent 5,405,597; April 11, 1995)
7. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 5,508,020; April 16, 1996)
8. Dean RT, Lister-James J, Civitello ER. Radiolabeled Compounds for Thrombus Imaging. (U.S. Patent 5,645,815; July 8, 1997)
9. Dean RT, Lister-James J. Radioactively Labeled Somatostatin-Derived Peptides for Imaging and Therapeutic Uses. (U.S. Patent 5,716,596; February 10, 1998)
10. Dean RT, Buttram S, McBride W, Lister-James J, Civitello ER. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 5,720,934; February 24, 1998)
11. Dean RT, Buttram S, McBride WP, Lister-James J, Civitello ER. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 5,776,428; July 7, 1998)
12. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 5,780,007; July 14, 1998)
13. Dean RT, Lister-James J. Radioactively Labeled Somatostatin-Derived Peptides for Imaging and Therapeutic Uses. (U.S. Patent 5,814,298; September 29, 1998)
14. Dean RT, Lister-James J. Somatostatin-Derived Peptides for Imaging and Therapeutic Uses. (U.S. Patent 5,820,845; October 13, 1998)
15. Dean RT, Lister-James J, Civitello ER, McBride WP. Radiolabeled Compounds for Thrombus Imaging. (U.S. Patent 5,830,856; November 3, 1998)

16. Dean RT, Lister-James J. Somatostatin-Derived Peptides for Imaging and Therapeutic Uses. (U.S. Patent 5,833,942; November 10, 1998)
17. Dean RT, Lister-James J. Radioactively Labeled Somatostatin-Derived Peptides for Imaging and Therapeutic Uses. (U.S. Patent 5,843,401; December 1, 1998)
18. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for Thrombus Imaging. (U.S. Patent 5,849,260; December 15, 1998)
19. Dean RT, Pearson DA, Lister-James J, Civitello ER. Radiolabeled Vasoactive Intestinal Peptides for Diagnosis and Therapy. (U.S. Patent 5,849,261; December 15, 1998)
20. Dean RT, Lister-James J. Radioactively Labeled Somatostatin-Derived Peptides for Imaging and Therapeutic Uses. (U.S. Patent 5,871,711; February 16, 1999)
21. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for Thrombus Imaging. (U.S. Patent 5,879,658; March 9, 1999)
22. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for GPIIB/IIIA Ligands Useful for Thrombus Imaging. (U.S. Patent 5,888,474; March 30, 1999)
23. Dean RT, Buttram S, McBride W, Lister-James J, Civitello ER. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 5,922,303; July 13, 1999)
24. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for Thrombus Imaging. (U.S. Patent 5,925,331; July 20, 1999)
25. Dean RT, McBride W, Lister-James J. Cyclic Peptide Somatostatin Analogs. (U.S. Patent 5,932,189; August 3, 1999)
26. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 5,951,964; September 14, 1999)
27. Dean RT, McBride W, Lister-James J. Cyclic Hexapeptide Somatostatin Analogues. (U.S. Patent 5,955,426; September 21, 1999)
28. Dean RT, Buttram S, McBride WP, Lister-James J, Civitello ER. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 5,965,107; October 12, 1998)
29. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for Thrombus Imaging. (U.S. Patent 5,968,476; October 19, 1999)
30. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 5,976,494; November 2, 1999)
31. Dean RT, Lister-James J. Labeled Somatostatin Analogs for Imaging Cardiovascular Disease. (U.S. Patent 5,976,496; November 2, 1999)
32. Dean RT, Lister-James J. Multimeric Polyvalent Antithrombotic Agents. (U.S. Patent 5,977,064; November 2, 1999)
33. Dean RT, Lees RS, Buttram S, Lister-James J. Technetium-99m Labeled Peptides for Imaging Inflammation. (U.S. Patent 5,989,519; November 23, 1996)
34. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 5,997,844; December 7, 1999)
35. Dean RT, Lees RS, Buttram S, Lister-James J. Technetium-99m Labeled Peptides for Imaging Inflammation. (U.S. Patent 5,997,845; December 7, 1999)
36. Dean RT, Pearson DA, Lister-James J, Civitello ER. Radiolabeled Vasoactive Intestinal Peptides for Diagnosis and Therapy. (U.S. Patent 6,007,792; December 28, 1999)
37. Dean RT, McBride W, Lister-James J. Radiolabeled Somatostatin Receptor-Binding Peptides. (U.S. Patent 6,017,509; January 25, 2000)

38. Dean RT, McBride W, Lister-James J. Radiolabeled Peptides. (U.S. Patent 6,017,512; January 25, 2000)
39. Dean RT, Lister-James J. Radiolabeled Compounds for Thrombus Imaging. (U.S. Patent 6,022,520; February 8, 2000)
40. Dean RT, Lister-James J. Radiolabeled Compounds for Thrombus Imaging. (U.S. Patent 6,022,857; February 8, 2000)
41. Dean RT, Lister-James J. Pharmaceutical Compositions for Imaging and treating thrombi (U.S. Patent 6,028,056; February 22, 2000)
42. Dean RT, Lister-James J, McBride W. Radiolabeled Somatostatin-Derived Peptides for Imaging and Therapeutic Uses. (U.S. Patent 6,015,206; April 18, 2000)
43. McBride W, Dean RT, Lister-James J, Civitello ER. Radiolabeled Compounds for Thrombus Imaging. (U.S. Patent 6,056,940; February 8, 2000)
44. Dean RT, Buttram S, McBride WP, Lister-James J, Civitello ER. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 6,074,627; June 13, 2000)
45. Dean RT, Bush LR, Pearson DA, Lister-James J. Calcitonin Receptor Binding Reagents. (U.S. Patent 6,083,480; July 4, 2000)
46. Dean RT, Lister-James J. Thrombus Imaging Agents. (U.S. Patent 6,083,481; July 4, 2000)
47. Dean RT, Buttram S, McBride WP, Lister-James J, Civitello ER. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 6,086,849; July 11, 2000)
48. Dean RT, Bush LR, Pearson DA, Lister-James J. Calcitonin Receptor Binding Reagents. (U.S. Patent 6,086,850; July 4, 2000)
49. Dean RT, Buttram S, McBride WP, Lister-James J, Civitello ER. Bisamine Bisthiol Radiolabel Binding Moieties. (U.S. Patent 6,093,383; July 25, 2000)
50. Dean RT, Lister-James J. Technetium-99m Labeled Peptides for Imaging. (U.S. Patent 6,113,878; September 5, 2000)
51. Dean RT, Lister-James J. Multimeric Antithrombotic Agents. (U.S. Patent 6,136,782; October 24, 2000)
52. Dean RT, Lister-James J. Multimeric Antithrombotic Agents. (U.S. Patent 6,150,329; November 21, 2000)
53. Dean RT, Lister-James J, Venuti MC, Somers TC. Benzodiazepine Derivatives for Imaging Thrombi. (U.S. Patent 6,171,578; January 9, 2001)
54. Dean RT, Lister-James J. Somatostatin Analogs. (U.S. Patent 6,183,722; February 6, 2001)
55. Dean RT, Lister-James J. Scintigraphic Imaging Agents. (U.S. Patent 6,248,304; June 19, 2001)
56. Lister-James J, Dean RT, Pearson DA, Wilson DM. Somatostatin Analogs. (U.S. Patent 6,358,491; March 19, 2002)

Abstracts:

1. Jones AG, Davison A, Brodack JW, Brenner D, Lister-James J, Costello CE, Lock CJL, Franklin KJ, LaTegola-Graff MR, Orvig C, Sohn M. Oxotechnetium Complexes Containing TcON₂S₂ Cores. J Labelled Compd Radiopharm 1982;19:1608

2. Homan BL, Lee RGL, Hill TC, Lovett RD, Lister-James J. A Comparison of 2 Cerebral Blood-flow Tracers, N-Isopropyl I-123 p-Iodoamphetamine and I-123 HIPDM. *J Nucl Med* 1983;24:P6
3. Fritzberg AR, Kasina S, Eshima D, Johnson DL, Jones AG, Lister-James J, Davison A, Brodack JW. Synthesis and Evaluation of N_2S_2 Complexes of Tc-99m as Renal Function Agents. *J Nucl Med* 1984;25:P16
4. Holman BL, Jones AG, Lister-James J, Davison A, Abrams MJ, Tumeh S, Nesto RW. A New Myocardial Imaging Agent, Tc-99m Hexakis(tert-butylisonitrile) technetium(+1) (TBI)-Studies in the Normal Human. *Circulation* 1984;70:124
5. Lister-James J, Brenner D, Davison A, Fritzberg AR, Jones AG. Carboxylic Acid Derivatives of Oxotechnetium(+5) Bismido Bisthiolates. *J Labelled Compd Radiopharm* 1984;21:1012-1013
6. Angelburger P, Dudczak R, Jones AG, Lister-James J, Wagner-Loeffler M, Buchkeit O, Kally F. Optimized Synthesis, Radiochromatography and Biodistribution of 99mTc-hexakis(t-butylisonitrile) technetium(I) ($^{99m}\text{Tc-TBI}$). *J Nucl Med Allied Sciences* 1985;29:186-187
7. Campbell S, Holman BL, Kirshenbaum JM, Jones AG, Davison A, Antman EM. Detection of Myocardial-Infarction Using Technetium-99m Tert-Butyl Isonitrile (Tc-99m TBI) Myocardial Scintigraphy. *Circulation* 1985;72:443
8. Campbell S, Kirshenbaum JM, Lister-James J, Jones AG, Davison A, Antman E. Radionuclide Imaging of Myocardial Infarction Using Tc-99m TBI. *J Nucl Med* 1985;26:P33-P34
9. Davison A, Jones AG, Lister-James J, Costello CE. Fatty Acid Derivatives-Substituted with a Neutral Technetium Complex. *J Nucl Med* 1985;26:P4
10. Holman BL, Campbell CI, Lister-James J, Jones AG, Kloner RA. The Effect of Hyperemia on the Biodistribution of the Myocardial Imaging Agent, Tc-99m TBI. *J Nucl Med* 1985;26:P13
11. Jones AG, Lister-James J, Costello CE, Davison A. x-Substituted Fatty Acid Derived from Neutral N_2S_2 -Oxotechnetium Chelates. *J Nucl Med Allied Sciences* 1985;29:201
12. Kronauge JF, Jones AG, Davison A, Lister-James J, Williams SJ, Mousa SA. Isonitrile Ester Complexes of Technetium. *J Nucl Med* 1986;27:894
13. Sia STB, Campbell S, Lister-James J, Davison A, Kronauge J, English R, Jones A, Holman BL. Myocardial Perfusion Imaging with Technetium 99m-Carbomethoxyisopropyl Isonitrile (Tc-99m CPI) in Exercise Studies. *Circulation* 1986;74:296
14. Sporn V, Perez-Balino N, Holman BL, Jones AG, Davison A, Camin L, Liprandi IS, Masoli O, Kronauge JF, Lister-James J, Mitta AEA, Sia STB, Campbell S. Myocardial Imaging with Tc-99m CPI: Initial Experience in the Human. *J Nucl Med* 1986;27:878
15. Vikydal R, Dudczak R, Schmoliner R, Angelburger P, Jones AG, Lister-James J. Myocardial Imaging with Tc-99m TBI at Rest and after Dipyridamol (DPM) Stress. *J Nucl Med* 1986;27:878
16. Bryson N, Davison A, Jones AG, Lister-James J. Neutral Technetium Complexes Synthesis Characterization and Reactivity. *J Nucl Med* 1987;28:728-729

17. Bryson N, Davison A, Jones AG, Brenner D, Lister-James J. Amides Thiulates and Technetium Chemistry and Design Implications. *J Nucl Med* 1987;28:593-594
18. Kronauge JF, Davison A, Lister-James J, Noska MA, Jones AG. Interspecies Comparison of the Distribution of Technetium CPI. *J Nucl Med* 1987;28:601-602
19. Piwnica-Worms D, Kronauge JF, Lister-James J, Holman BL, Davison A, Jones AG. Cellular Kinetics and Binding Characteristics of Hexakis (alkylisonitrile) technetium(I) Complexes in Cultured Chick Heart Cells. *Investigative Radiology* 1987;22:S23
20. Pak KY, Dean RT, Mattis JA, Lister-James J, Shealy D, Stewart R, Berger H. Effects of Trace Metals Ion Contamination on the In-111 Radiolabeling of Antimyosin Fab'-DTPA. *J Nucl Med* 1988;29:923-924
21. Epps LA, Sun L, Arevalo M, Ghrayeb J, Nedelman M, Fogler WE, Lister-James J. Technetium (Tc-99m) Labeled Genetically Engineered Chimeric 17-1A G4K/Metallothionein Antibody. *J Nucl Med* 1989;30:794
22. Davison A, Lister-James J, Bryson N, Jones AG. Sulfur protecting groups in the preparation of Technetium-V Thiolate complexes. *J Labelled Compd Radiopharm* 1989;26:264-265
23. Dean RT, Weber R, Boutin R, Nedelman MA, Lister-James J. Ester-Linked Tc-99m Labeled Antibody-Bifunctional Chelator Conjugates Having Enhanced Whole-body Clearance. *J Nucl Med* 1989;30:934
24. Lister-James J, Weber R, Boutin R, Nedelman MA, Dean RT. Site-Specifically Tc-99m Labeled Antibody-Bifunctional Chelator Conjugates. *J Nucl Med* 1989;30:793
25. Dean RT, Weber R, Boutin R, Nedelman M, Lister-James J. Chelating Ligands for Labeling Protein-Ligand Conjugates with Tc-99m. In "Technetium and Rhenium in Chemistry and Nuclear Medicine" Ed. M. Nicolini, Bandoli G, Mazzi U. Cortina International, Verona 1990;581-584
26. Dean RT, Weber R, Pak K, Boutin R, Buttram S, Nedelman M, Lister-James J. New Facile Methods for Stably Labeling Antibodies with Technetium-99m. In "Technetium and Rhenium in Chemistry and Nuclear Medicine" Ed. M Nicolini, Bandoli G, Mazzi U. Cortina International, Verona 1990;605-607
27. Nedelman MA, Schaible TF, Manspeaker HF, Iuliucci JD, Lister-James J, Berger HJ. Evaluation of Antimyosin Uptake in Reversibly Injured (Stunned) Myocardium. *J Nucl Med* 1990;31:795
28. Nedelman MA, Lister-James J, Weber RW, Boutin R, Berger HJ, Dean RT. Accelerated Renal Clearance of Tc-99m Antimyosin Fab'. *J Nucl Med* 1990;31:833
29. Shealy D, Nedelman M, Tai M-S, Huston JS, Berger H, Lister-James J, Dean RT. Characterization and Biodistribution of Tc-99m Labeled Single Chain Antibody Fv Fragment (sFv). *J Nucl Med* 1990;31:776
30. Weber RW, Lister-James J, Nedelman MA, Boutin R, Dean RT. Hydrolysis of an Ester Linked Tc-99m Labeled Antibody Fab' Chelator Conjugate: Characterization of the Hydrolysis Product. *J Nucl Med* 1990;31:905
31. Weber RW, Nedelman M, Lister-James J, Dean RT. Comparison of Technetium-99m-Labeled Antibody Fab' Chelator Conjugates having Mono Di and Triester Linkages. *J Labelled Compd Radiopharm* 1991;30:308

32. Dean RT, Lister-James J, Lees RS, Lees AM, Vallabhajosula S, Goldsmith SJ. Peptides in Biomedical Sciences: Principles and Practice. Radiolabeled Blood Elements: Recent Advances in Techniques and Applications; Sixth Symposium of the International Society of Radiolabeled Blood Elements, Barcelona, Spain Martin-Comin J, et al. (Ed.). NATO ASI Series A Life Sciences 1992;262
33. Hardoff R, Zanzonico P, Braegelman F, Herrold EM, Lees RS, Lees AM, Lister-James J, Dean R, Borer JS. Autoradiographic Identification of Atherosclerosis with Iodine-125 SP4. *Circulation* 1992;86:845
34. Vallabhajosula S, Goldsmith SJ, Buttram S, Lister-James J, Dean RT. Noninvasive Imaging of Atherosclerotic Lesions in Rabbits with Technetium-99m Labeled Peptides. *Circulation* 1992;86:1709
35. Hardoff R, Zanzonico P, Braegelman F, Herrold EM, Lees RS, Lees AM, Lister-James J, Dean RT, Borer JS. Accumulation of Technetium-99m in Atherosclerotic Lesions in Aorta and Carotid Arteries in Watanabe Heritable Hyperlipidemic Rabbits. *Clin Res* 1993;41:231A
36. Hardoff R, Zanzonico PB, Braegelman F, Lu P, Herrold EM, Lees RS, Lees AM, Lister-James J, Dean RT, Borer JS. Atherosclerosis Imaging with Technetium-99m Labeled APOB Synthetic Peptides in Hyperlipidemic Rabbits. *J Nucl Med* 1993;34:66P
37. Knight LC, Lister-James J, Dean RT, Maurer AH. Evaluation of Technetium-99m Labeled Cyclic Peptides for Thrombus Imaging. *J Nucl Med* 1993;34:17P-18P
38. Stubbs JB, Vallabhajosula S, Lister-James J, Smith TD. Radiation Dose Estimates for Technetium-99m P215 a Peptide for Imaging of Atherosclerotic Plaques. 40th Annual Meeting of the Society of Nuclear Medicine, Toronto, Canada 1993;156P
39. Vallabhajosula S, Ali KS, Goldsmith SJ, Lipszyc H, Bastidas DA, Lister-James J, Buttram S, Moyer BR, Dean RT. Evaluation of Technetium-99m Labeled Peptides for Imaging Infection in a Rabbit Model. *J Nucl Med* 1993;34:104P
40. Vallabhajosula S, Ali KSM, Goldsmith SJ, Lipszyc H, Bastidas DA, Lister-James J, Buttram S, Dean RT. Evaluation of Technetium-99m Labeled Peptides for Imaging Atherosclerotic Lesions In-Vivo. *J Nucl Med* 1993;34:66P
41. Lister-James J, McBride WJ, Moyer BR, Buttram S, Vallabhajosula S, Bastidas DA, Lipszyc H, Lee H, Dean RT. A Structure-Activity-Relationship (SAR) Study of Somatostatin Receptor-Binding Peptides Radiolabeled with Tc-99m. 1994; *J Nucl Med* 1994;35:257P-258P
42. Lister-James J, Moyer BR, Buttram S, Knight LC, Vallabhajosula S, Dean RT. A Structure-Activity-Relationship (SAR) Study of GPIIb-IIIa Receptor-Binding Peptides Radiolabeled with Tc-99m for Imaging Thromboembolism. *J Nucl Med* 1994;35:257P
43. Lu P, Zanzonico P, Lister-James J, Herrold E, Lees R, Lees A, Dean RT, Borer JS. Comparisons in Rabbits of Tc-99m-Labeled Synthetic Peptide Fragments for Imaging of Atherosclerotic Plaque. *J Nucl Med* 1994;35:80P
44. Vallabhajosula S, Lipszyc H, Lister-James J, Buttram S, Moyer B, Dean RT. Tc-99m Labeled Peptides: Site and Nature of Radiolabeling and its Effect on Pharmacokinetics and Biodistribution. *J of Labelled Compd and Radiopharm* 1994;35:43-45

45. Diggles L, Pham HL, Marcus C, Minami C, Mason G, Stubbs J, Sparks R, Bernardy JD, Lister-James J. Biodistribution and Dosimetry of Tc-99m 280: A Phase I study. *J Nucl Med* 1995;36:183P
46. Lister-James J, McBride BJ, Pearson DA, Moyer BR, Vallabhajosula S, Dean RT. Tc-99m P829: A Somatostatin Receptor-Binding Techtide for Imaging Somatostatin Receptors In Vivo. *J Nucl Med* 1995;36:91P
47. Lister-James J, McBride BJ, Pearson DA, De Rosch MA, Moyer BR, Bush LR, Vallabhajosula S, Dean RT. Tc-99m P748: A Receptor-Binding Techtide for Imaging Activated Platelets. *J Nucl Med* 1995;36:16P-17P
48. Lu P, Zanzonico P, Lister-James J, Goldfine SM, Moyer BR, Herrold EM, Lees RS, Lees AM, Dean RT, Borer JS. I-125-Labeled Synthetic Peptide Fragment: Biodistribution and Localization in Experimental Atherosclerosis. *J Nucl Med* 1995;36:25P
49. Lu P, Zanzonico P, Lister-James J, Herrold EM, Lees RS, Lees AM, Dean RT, Borer JS. Atherosclerotic Plaques Imaged by Tc-99m Labeled Synthetic Peptide. *J of the American College of Cardiology* 1995;Spec Issue:29A
50. Moyer BR, Vallabhajosula S, Lister-James J, Cyr JE, Bastidas D, Lipszyc H, Snow DA, Bush LR, Dean RT. Development of a White Blood Cells Specific Technetium-99m Imaging Agent from PF-4 for Detecting Infection. *J Nucl Med* 1995;36:161P
51. Pham HL, Diggles L, Marcus CS, Sinow R, Mason G, Renslo R, Minami C, Bernardy JD, Lister-James J. The detection of Venous Thrombosis (VT) with Tc-99m P280 Labeled Synthetic Peptide. *J Nucl Med* 1995;36:89P
52. Vallabhajosula S, Moyer BR, Lister-James J, Lipszyc H, Zhao QH, Bastidas DA, Machac J, Dean RT. Tc-99m-P829: Somatostatin Receptor (SSTR) Binding Techtide: Comparison Tumor Uptake with In-111-Octreotide in Rats with Pancreatic Tumor. *J Nucl Med* 1995;36:192P
53. Vallabhajosula S, Lister-James J, Machac J, Moyer BR, Zhao QH, Bastidas DA, Lipszyc H, Dean RT. Tc-99m-P748: Activated Platelet Specific Techtide for Imaging Thrombus: Comparison with In-111-Platelets in a Canine Model of DVT. *J Nucl Med* 1995;36:103P
54. Lastoria S, Muto P, Acampa W, Caraco C, Vergara E, Varrella P, Pezzulla L, Ionna F, Mozzillo N, Lister-James J, Salvatore M. Somatostatin Receptor Scintigraphy (SRS) with Technetium-99m Labeled Synthetic Peptides in Melanoma. *J Nucl Med* 1996;37:138P
55. Lees RS, Lees AM, Lister-James J, Dean RT. Radiopharmaceutical Imaging of Atherosclerosis. *Boston Heart Found, Cambridge MA* 1996;119-124
56. Moyer BR, Vallabhajosula S, Bush LR, Chan Y-W, Lister-James J, Dean RT. Infection Imaging with a White Blood Cell Specific Tc-99m PGG-Glucan (PGG-1): Comparison with In-111 WBCs In Vitro and In Vivo. *J Nucl Med* 1996;37:204P-205P
57. Vallabhajosula S, Weinberger J, Machac J, Lister-James J, Dean RT, Lipszyc H, Patel SL, Harrington E, Harrington M. Technetium-99m P280, Activated Platelet Specific Techtide: Phase II Clinical Studies in Patient with Carotid Atherosclerosis. *J Nucl Med* 1996;37

58. Vallabhajosula S, Lister-James J, Dean RT, Padurean A, Gallo R, Bastidas D, Lipszyc H, Zhao QH, Machac J. Technetium-99m-P748, Platelet Specific Techtide for Imaging Arterial Thrombus: Preclinical Studies in a Canine Model of Intra-Arterial Thrombus. *J Nucl Med* 1996;37:152P
59. Virgolini I, Yang Q, Angelberger P, Leimer M, Lister-James J, Kaserer K, Li SR, Neuhold N, Lehner H, Krois D, Maecke H, Valent P. Comparative In Vitro Studies with Six Radiolabeled Somatostatin Analogs. *J Nucl Med* 1996;37:20P-21P
60. Handmaker H, Lister-James J, Dann RW, Baran YM, Abernathy H. Scintigraphic Assessment of Hodgkin's and non-Hodgkin's Lymphoma Patients with a Novel SSSTR Binding Peptide-Technetium Tc-99m P829. *J Nucl Med* 1997;38:236P
61. Lister-James J, Vallabhajosula S, Moyer BR, Pearson DA, McBride BJ, De Rosch MA, Bush LR, Machac J, Dean RT. Pre-Clinical Evaluation of Technetium-99m Platelet Receptor-Binding Peptide. *J Nucl Med* 1997;38:105-111
62. Handmaker H, Mohler KT, Dann RW, Lister-James J, Baran YM. Oncoscintigraphy of Neuroendocrine and Non-neuroendocrine Tumors with a Novel SSR Binding Peptide-technetium Tc-99m P829-Preliminary Experience in 39 Patients. *Clin Nucl Med* 1997;22:350P
63. Leimer M, Kurtaran A, Raderer M, Smith-Jones P, Bischof C, Petcov W, Brunner C, Schima W, Lister-James J, Virgolini I. Somatostatin Receptor In Vitro and In Vivo Binding of Tc-99m P829. *J Nucl Med* 1998;39:39P
64. Lister-James J, Virgolini I, Nelson CA, Pearson DA, Leimer M, Moyer BR, Wilson DM, Dean RT. Tc-99m 1666: Development of a Technetium-99m-Labeled VIP-Receptor Imaging Agent. *J Nucl Med* 1998;39:225P-226P
65. Leimer M, Kurtaran A, Raderer M, Smith-Jones P, Bischof C, Valencak J, Schima W, Lister-James J, Virgolini I. *In Vitro* and *In Vivo* binding of 99mTc-P829 to gastrointestinal adenocarcinomas. *Eur J Nucl Med* 1998; 25(8):923P
66. Shirzad M, Leimer M, Lister-James J, Moyer BR, Angelberger P, Virgolini I. Preclinical characterization of a 99mTechnetium labeled Vasoactive Intestinal Peptide (VIP) receptor imaging peptide. *Eur J Nucl Med* 1998; 25(8):977P
67. Srivastava SC, Meinken GE, Lister-James J. Characterization and in-vivo testing of HPLC-purified Sn-117m stannic DTPA preparations. *Eur J Nucl Med* 1998; 25(8):979P
68. Cyr JE, Nelson CA, Pearson DA, De Rosch MA, Rutkowski JV, Lister-James J, Dean RT. Tc 99m Radiolabeling and biological evaluation of a new GPIIb/IIIa receptor binding agent, P424. *J Nucl Med* 1999; 40(5):198P
69. Nelson CT, Moyer BR, Manchanda R, Pearson DA, Rutkowski JV, Lister-James J, Dean RT. A peptide analog of calcitonin labeled with Tc 99m targets MCF-7 human breast cancer xenografts in nude mice. *J Nucl Med* 1999; 40(5):103P
70. Virgolini I, Traub T, Ofluoglu S, Kurtaran A, Raderer M, Li SR, Beck M, Leimer M, Angelberger P, Havlik E, Dudozak R, Lister-James J. Human biodistribution, safety and absorbed dose of ^{99m}Tc-1666 vasoactive intestinal peptide (VIP) receptor scintigraphy. *J Nucl Med* 1999; 40(5):244P
71. Moyer BR, Manchanda R, De Rosch MA, Rutkowski JV, Nelson CA, Guaraldi MS, Lister-James J, Dean RT. Effect of graded white blood cell depletion by mechlorethamine on the infection uptake and pharmacokinetics of Tc 99m P483H in the *E. Coli* infected rabbit. *J Nucl Med* 1999; 40(5):213P-214P

72. Nelson CA, Moyer BR, Manchanda R, Pearson DA, Rutkowski JV, De Rosch MA, Moyer C, Lister-James J, Dean RT. FITC and Tc 99m labeled P483H bind specifically to human monocytes and polymorphonuclear leukocytes with high capacity. *J Nucl Med* 1999; 40(5):213P
73. Palestro CJ, Thomas MB, Bhargava KK, Afriyir MO, Nicodemeus CF, Lister-James J, Dean RT. ^{99m}Tc P483H for imaging infection Phase 2 multicenter trial results. *J Nucl Med* 1999; 40(5):15P
74. Kurtaran A, Leimer M, Raderer M, Schima W, Smith-Jones P, Lister-James J, Virgolini I. Somatostatin receptor (SSTR) scintigraphy (^{99m}Tc-P829) in the clinical management of gastrointestinal adenocarcinomas. *J Nucl Med* 1999; 40(5):244P
75. Cyr JE, Pearson DA, Manchanda R, Francesconi LC, De Rosch MA, Rutkowski JV, Nelson CA, Moyer BR, Lister-James J, Dean RT. Characterization and radiolabeling of Tc 99m depreotide: a somatostatin receptor binding tumor imaging agent. *J Nucl Med* 1999; 40(5):80P
76. Blum J, Handmaker H, Lister-James J, Rinne N. A multicenter trial with somatostatin analog Tc99m-depreotide (NeoTect™) in the evaluation of solitary pulmonary nodules. *J Nucl Med* 1999; 40(5):10P
77. Taillefer R, Lister-James J, Dean RT. Tc-99m apcitide (AcuTect™): sensitivity and specificity for imaging acute deep vein thrombosis. *J Nucl Med* 1999; 40(5):11P
78. Blum J, Handmaker H, Lister-James J, Rinne N and the Multicenter Solitary Pulmonary Nodule Study Group. Tc-99m Depreotide (Neospect™) imaging of malignant solitary pulmonary nodules: results of a multi-center clinical trial. *Eur J Nucl Med* 1999; 26(9):966P
79. Virgolini I, Traub T, Ofluoglu S, Kurtaran A, Raderer M, Beck M, Leimer M, Angelberger P, Li SR, Novotny C, Havlik E, Dudczak R, Lister-James J. Tc-99m P1666 vasoactive intestinal peptide (VIP) receptor scintigraphy: clinical efficacy, biodistribution and safety. *Eur J Nucl Med* 1999; 26(9):1154P
80. Handmaker H, Blum JE, Gambhir SS, Lister-James J. A proposed new diagnostic algorithm for the preoperative evaluation of solitary pulmonary nodules. *Radiology* Nov 1999; 213:162(P)
81. Virgolini I, Traub T, Ofluoglu S, Kurtaran A, Raderer M, Beck M, Leimer M, Angelberger P, Li SR, Novotny C, Havlik E, Dudczak R, Lister-James J. Tc-99m P1666 vasoactive intestinal peptide (VIP) receptor scintigraphy: clinical efficacy, biodistribution and safety. *Eur J Nucl Med* 1999; 26(9):1154P
82. Handmaker H, Blum JE, Gambhir SS, Lister-James J. A proposed new diagnostic algorithm for the preoperative evaluation of solitary pulmonary nodules. *Radiology* Nov 1999; 213:162P
83. Nelson CA, Pearson DA, Wilson DM, Guaraldi MT, Moyer BR, Azure MT, Jones WB, Lister-James J, Dean RT. Biodistribution of a novel somatostatin receptor-binding peptide in rat pancreatic and human lung tumor murine xenografts. *J Nucl Med* May 2000;41(5 suppl):260P
84. Moyer BR, Guaraldi MT, Azure MT, Rusckowski M, Cyr JE, Jones WB, Nelson CA, DeRosch MA, Lister-James J, Dean RT. The Kinetics of Re 188 P2045, A New SSTR Radiotherapeutic, in the S-D Rat, NZW Rabbit and Rhesus Monkey. *Eur J Nucl Med* August 2000;27(8 suppl):975P

85. Azure MT, Guaraldi MT, Zinn KR, Coan PN, Pearson DA, Wilson DM, Cyr JE, Manchanda R, Lister-James J, Dean RT. Dosimetry Evaluation of ^{188}Re P2045 in Primates as Determined by Necropsy and Scintigraphic Region of Interest Analysis Biodistribution Methods. J Nucl Med June 2001;42 (5 suppl):69P
86. Bugaj JE, Bickel EM, Azure MT, Friebe M, Lister-James J, Dean RT, Dinkelborg LM. Radiotherapeutic Efficacy of a SSTR-Targeting Peptide (^{188}Re -P2045) in a Small Cell Lung Cancer (SCLC) Mouse Model. J Nucl Med June 2002;43 (5 suppl):123